Education
About Us
Working with TipRanks
Follow Us
Virpax Pharmaceuticals (VRPX)
NASDAQ:VRPX
RESEARCH TOOLSreports
VRPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.85 - $106.75
Previous CloseN/A
Volume440.71K
Average Volume (3M)614.72K
Market Cap
$2.57M
Enterprise Value$3.22M
Total Cash (Recent Filing)$1.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Mar 26, 2025EPS Estimate
-9.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-128.83
Shares Outstanding1,242,504
10 Day Avg. Volume672,733
30 Day Avg. Volume614,721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsProbudur found to successfully reduce pain in rat model, with positive study results consistent with prior studies.
SafetyThe Molecular Envelope Technology (MET) study found no moderate-to-severe adverse events, indicating safety.
Bears Say
Financial ConstraintsVirpax is capital constrained to file INDs and advance the products into clinical trials.
Financing RisksVirpax did not consummate a ≥$5M financing with an institutional investor as previously agreed upon, increasing the risk that the financing cannot be completed.
Leadership ChangesLeadership departures and organizational restructuring have led to a lack of clarity on the clinical path forward.
---
Ownership Overview
0.12%
Insiders
0.18% Mutual Funds
0.09% Other Institutional Investors
99.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRPX FAQ
What was Virpax Pharmaceuticals’s price range in the past 12 months?
Virpax Pharmaceuticals lowest stock price was $1.85 and its highest was $106.75 in the past 12 months.
What is Virpax Pharmaceuticals’s market cap?
Virpax Pharmaceuticals’s market cap is $2.57M.
When is Virpax Pharmaceuticals’s upcoming earnings report date?
Virpax Pharmaceuticals’s upcoming earnings report date is Mar 26, 2025 which is today.
How were Virpax Pharmaceuticals’s earnings last quarter?
Virpax Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.54 earnings per share for the quarter, the consensus estimate of -$0.54 by $0.
Is Virpax Pharmaceuticals overvalued?
According to Wall Street analysts Virpax Pharmaceuticals’s price is currently Overvalued.
Does Virpax Pharmaceuticals pay dividends?
Virpax Pharmaceuticals does not currently pay dividends.
What is Virpax Pharmaceuticals’s EPS estimate?
Virpax Pharmaceuticals’s EPS estimate is -9.25.
How many shares outstanding does Virpax Pharmaceuticals have?
Virpax Pharmaceuticals has 1,242,504 shares outstanding.
What happened to Virpax Pharmaceuticals’s price movement after its last earnings report?
Virpax Pharmaceuticals reported an EPS of -$0.54 in its last earnings report, expectations of -$0.54. Following the earnings report the stock price went down -6.288%.
Which hedge fund is a major shareholder of Virpax Pharmaceuticals?
Currently, no hedge funds are holding shares in VRPX
---
Virpax Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.00%
12-Months-Change
Fundamentals
Return on Equity
-2364.82%
Trailing 12-Months
Asset Growth
-83.84%
Trailing 12-Months
Company Description
Virpax Pharmaceuticals
Virpax Pharmaceuticals (VRPX) is a clinical-stage pharmaceutical company focused on developing novel drug delivery systems to enhance the efficacy and safety of existing therapeutics. The company primarily operates in the pharmaceutical sector, specializing in pain management, neurological disorders, and anti-viral therapies. By leveraging proprietary delivery technologies, Virpax aims to optimize the delivery of active pharmaceutical ingredients, ultimately improving patient outcomes.
---
VRPX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aurinia Pharmaceuticals
―
ESSA Pharma
―
AnaptysBio
―
Kala Pharmaceuticals
―
Kezar Life Sciences
―
---